Dudediligence.

NextCure, Inc

NXTCNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Net income, by quarter
−$11.5MSep ’24−$11.6MDec ’24−$11.0MMar ’25−$26.8MJun ’25−$8.6MSep ’25−$9.4MDec ’25−$9.8MMar ’26−$14.9MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating income−$70.8M−$75.9M−$67.6M−$59.7M−$57.6M
Net income−$69.4M−$74.7M−$62.7M−$55.7M−$55.8M
Operating cash flow−$57.3M−$53.9M−$53.0M−$40.8M−$49.6M
Free cash flow−$59.6M−$56.0M−$53.8M−$41.3Mnone on file
Cash$12.3M$26.6M$13.1M$27.7M$26.0M
Shares outstanding27.7M27.8M27.9M2.3M3.5M